Rep. Josh Gottheimer Buys Johnson & Johnson (NYSE:JNJ) Shares

Posted by Jessica Moore on Feb 12th, 2025

Representative Josh Gottheimer (D-New Jersey) recently bought shares of Johnson & Johnson (NYSE:JNJ). In a filing disclosed on February 10th, the Representative disclosed that they had bought between $1,001 and $15,000 in Johnson & Johnson stock on January 24th. The trade occurred in the Representative’s “MORGAN STANLEY – SELECT UMA ACCOUNT # 1” account.

Representative Josh Gottheimer also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 1/31/2025.
Sold $1,001 – $15,000 in shares of Arista Networks (NYSE:ANET) on 1/31/2025.
Purchased $1,001 – $15,000 in shares of Visa (NYSE:V) on 1/31/2025.
Purchased $1,001 – $15,000 in shares of Tesla (NASDAQ:TSLA) on 1/31/2025.
Purchased $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 1/31/2025.
Purchased $1,001 – $15,000 in shares of Twilio (NYSE:TWLO) on 1/31/2025.
Sold $1,001 – $15,000 in shares of ICF International (NASDAQ:ICFI) on 1/31/2025.
Purchased $1,001 – $15,000 in shares of Mastercard (NYSE:MA) on 1/31/2025.
Purchased $1,001 – $15,000 in shares of Visa (NYSE:V) on 1/30/2025.
Purchased $1,001 – $15,000 in shares of 3M (NYSE:MMM) on 1/30/2025.

Johnson & Johnson Stock Up 1.3 %

Shares of NYSE JNJ opened at $156.18 on Wednesday. The business has a 50-day simple moving average of $147.48 and a two-hundred day simple moving average of $156.01. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $168.85. The company has a market cap of $376.02 billion, a P/E ratio of 23.49, a P/E/G ratio of 2.46 and a beta of 0.52. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The company had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. During the same quarter in the previous year, the company earned $2.29 earnings per share. Johnson & Johnson’s revenue for the quarter was up 5.3% on a year-over-year basis. Research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.18%. Johnson & Johnson’s dividend payout ratio (DPR) is 74.59%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger bought 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The stock was bought at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the acquisition, the director now directly owns 1,000 shares in the company, valued at $147,220. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.16% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of recent analyst reports. Royal Bank of Canada reiterated an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research report on Thursday, January 23rd. Argus raised Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Morgan Stanley cut their price objective on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. Raymond James decreased their price objective on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research report on Thursday, January 23rd. Finally, Bank of America dropped their target price on shares of Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a research report on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $170.67.

View Our Latest Research Report on JNJ

Institutional Investors Weigh In On Johnson & Johnson

Hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. boosted its stake in shares of Johnson & Johnson by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 232,792,559 shares of the company’s stock valued at $33,666,460,000 after purchasing an additional 1,772,706 shares during the period. State Street Corp raised its holdings in Johnson & Johnson by 0.9% during the 3rd quarter. State Street Corp now owns 134,245,811 shares of the company’s stock valued at $21,755,874,000 after buying an additional 1,154,088 shares during the last quarter. Geode Capital Management LLC boosted its position in Johnson & Johnson by 1.8% during the 3rd quarter. Geode Capital Management LLC now owns 56,106,884 shares of the company’s stock valued at $9,064,149,000 after buying an additional 1,004,763 shares during the period. FMR LLC increased its position in shares of Johnson & Johnson by 7.4% in the third quarter. FMR LLC now owns 18,316,920 shares of the company’s stock valued at $2,968,440,000 after acquiring an additional 1,265,748 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Johnson & Johnson by 3.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 18,187,082 shares of the company’s stock valued at $2,630,216,000 after acquiring an additional 547,714 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

About Representative Gottheimer

Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey’s 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2027.

Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey’s 5th Congressional District. He declared candidacy for the 2026 election.

Gottheimer is also running for election for Governor of New Jersey. He declared candidacy for the Democratic primary scheduled on June 10, 2025.

Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.

Johnson & Johnson Company Profile

(Get Free Report)

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.